Group One Trading’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-59,000
| Closed | -$109K | – | 8476 |
|
|
2023
Q1 | $109K | Buy |
+59,000
| New | +$73.1K | ﹤0.01% | 4240 |
|
|
2022
Q4 | – | Sell |
-3,000
| Closed | -$7K | – | 8384 |
|
|
2022
Q3 | $7K | Buy |
3,000
+2,600
| +650% | +$9.21K | ﹤0.01% | 6722 |
|
|
2022
Q2 | $1K | Sell |
400
-100
| -20% | -$486 | ﹤0.01% | 7677 |
|
|
2022
Q1 | $3K | Sell |
500
-1,700
| -77% | -$12.1K | ﹤0.01% | 7680 |
|
|
2021
Q4 | $18K | Sell |
2,200
-21,600
| -91% | -$178K | ﹤0.01% | 7049 |
|
|
2021
Q3 | $177K | Buy |
23,800
+22,100
| +1,300% | +$137K | ﹤0.01% | 5309 |
|
|
2021
Q2 | $12K | Sell |
1,700
-8,100
| -83% | -$67.3K | ﹤0.01% | 7468 |
|
|
2021
Q1 | $101K | Sell |
9,800
-17,800
| -64% | -$195K | ﹤0.01% | 5655 |
|
|
2020
Q4 | $193K | Buy |
27,600
+10,600
| +62% | +$82.5K | ﹤0.01% | 4080 |
|
|
2020
Q3 | $139K | Sell |
17,000
-18,200
| -52% | -$113K | ﹤0.01% | 3941 |
|
|
2020
Q2 | $243K | Buy |
35,200
+33,800
| +2,414% | +$182K | ﹤0.01% | 3225 |
|
|
2020
Q1 | $7K | Sell |
1,400
-30,900
| -96% | -$178K | ﹤0.01% | 4704 |
|
|
2019
Q4 | $282K | Buy |
+32,300
| New | +$175K | ﹤0.01% | 2913 |
|
|
2019
Q2 | – | Sell |
-16,100
| Closed | -$100K | – | 5547 |
|
|
2019
Q1 | $100K | Buy |
16,100
+15,100
| +1,510% | +$73K | ﹤0.01% | 3182 |
|
|
2018
Q4 | $3K | Sell |
1,000
-86,100
| -99% | -$402K | ﹤0.01% | 4614 |
|
|
2018
Q3 | $566K | Sell |
87,100
-112,700
| -56% | -$838K | ﹤0.01% | 2177 |
|
|
2018
Q2 | $1.53M | Buy |
199,800
+108,000
| +118% | +$1.56M | 0.01% | 1324 |
|
|
2018
Q1 | $2.05M | Buy |
+91,800
| New | +$2.04M | 0.02% | 994 |
|
Other funds holding JNCE
Group One Trading's JNCE Position: Q4 2022 in Review
Group One Trading sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 2,334 shares — an estimated $5K sold.
Group One Trading first reported a position in JNCE in Q4 2017 and held it in 15 quarters. The position peaked at $276K in Q3 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.
- Group One Trading reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Group One Trading sold 2,334 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $5K.
- Group One Trading first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 15 quarters.
- Group One Trading's Jounce Therapeutics, Inc. Common Stock position peaked at $276K in Q3 2018.
- 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Group One Trading's 13F filing for Q4 2022, filed 9 Feb 2023.